CClinicalTrials.gg
Active, not recruitingNCT06633978MediDreamUpdated Aug 24, 2026

Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults

An interventional study of MediTrain and wrist worn multi-sensor watches in MCI and Aging, sponsored by University of California, San Francisco. Active, not recruiting at 1 site in United States. Open to participants aged 60 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
60 Years to 85 Years
Sex
All
01

Study summary

The goal of this proposed research is to collect pilot data to test the hypothesis that treatment with a novel form of closed-loop digital meditation (MediTrain) will lead to a greater magnitude of gains in cognitive abilities in patients with mild cognitive impairment (MCI), compared to OA without cognitive impairment, and will lead to improvements in quantitative measures of sleep.

02

Conditions studied

  • MCI
  • Aging

Keywords

  • meditation
  • sleep
  • stress
  • attention
  • cognition
  • memory
03

In context

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • comfortably ambulatory healthy physical condition
  • normal or corrected to normal visual
  • auditory acuity
  • fluency in spoken English
  • Between 60-85 years old
  • No neurological or psychiatric disorders
  • No substance abuse
  • Not taking anti-depressants
  • Not taking anti-anxiety medication
  • No history of seizures
  • No color blindness
  • No glaucoma
  • No macular degeneration
  • No amblyopia (lazy eye)
  • No strabismus (cross eyed)
  • Aneurysm clip(s)
  • No Cardiac pacemaker
  • No Implanted cardioverter defibrillator (ICD)
  • No Electronic implant or device
  • No Magnetically-activated implant or device
  • No Neurostimulation system
  • No Spinal cord stimulator
  • No Internal electrodes or wires
  • No Bone growth/bone fusion stimulator
  • No Cochlear, otologic, or other ear implant
  • No Insulin or other infusion pump
  • No Implanted drug infusion device
  • No type of prosthesis (eye, penile, etc.)
  • No Heart valve prosthesis
  • No Eyelid spring or wire
  • No Artificial or prosthetic limb
  • No Metallic stent, filter, or coil
  • No Shunt (spinal or intraventricular)
  • No Vascular access port and/or catheter
  • No Radiation seeds or implants
  • No Swan-Ganz or thermodilution catheter
  • No Medication patch (Nicotine, Nitroglycerine)
  • No metallic fragment or metallic foreign body in/on the body that can not be removed
  • No Wire mesh implant
  • No Tissue expander (e.g., breast)
  • No Surgical staples, clips, or metallic sutures
  • No Joint replacement (hip, knee, etc.)
  • No Bone/joint pin, screw, nail, wire, plate, etc.
  • No IUD, diaphragm, or pessary
  • No Dentures or partial plates that can not be removed
  • No Tattoo or permanent makeup
  • No Body piercing jewelry
  • No Claustrophobia
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    MediTrain

    Device: MediTrain · Device: wrist worn multi-sensor watches · Device: Sleep monitor

Interventions

  • DeviceMediTrain

    Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.

  • Devicewrist worn multi-sensor watches

    Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.

  • DeviceSleep monitor

    Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.

06

What researchers measure

Primary outcomes

  1. Mean change on the Continuous Performance Task (CPT) over time

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  2. Mean change in sleep quality

    Mean change in sleep quality (i.e., total sleep time / time in bed, therefore this measure incorporates latency to sleep onset, total sleep time, wake after sleep onset and early morning waking, with higher numbers associated with better sleep) over time \[Time Frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants\]

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  3. Mean change in measures of stress reactivity over time

    Measures of heart rate variability (HRV) and electrodermal activity (EDA) while participants perform a stress-inducing task

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

Secondary outcomes

  1. Mean change in Telomere length (quantified in peripheral blood cells) over time

    200 mL of blood will be collected from each participant before and after the intervention. Blood will be centrifuged for whole blood cell acquisition and stored at -80 °C for subsequent batch testing. Telomere length (T/S ratio) will be quantified in peripheral blood mononuclear cells.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  2. Mean change on a distracted attention task over time

    Mean performance on a distracted attention task will be compared pre and post intervention. Divided attention performance will be assessed using the Filter Task that places simultaneous demands on perceptual discrimination abilities and distraction filtering.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  3. Mean change in Frontal Theta Power over time

    Based on previous studies of meditation training and our preliminary data, we predict that MediTrain will lead to significantly enhanced midline frontal theta power during the TOVA in MCI as compared to OA. Beyond most prior studies, by collecting structural MRI data, we will be able to source-localize any observed changes in midline frontal theta.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  4. Mean change in resting state networks over time

    We also expect MediTrain will augment intrinsic Default Mode Network (DMN) connectivity, both functionally (measured with resting fMRI111,112) and structurally (measured with DTI-based connectomes). This is hypothesized based on the known association between the DMN,

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

Other outcomes

  1. Mean change on the Adaptive Cognitive Evaluation (ACE) over time

    The ACE is a mobile cognitive assessment tool, which includes a battery of cognitive control tests for rapid tests of cognition. The sub-tests (or 'modules') in ACE are adapted from standardized tasks to rapidly assess various aspects of cognition, including attention, memory, and multitasking. We will assess response time, accuracy, and response time variability in each case, with faster/more accurate/less variable performance being indicative of improved cognitive control, meditation, and frontal theta power.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  2. Mean change in continuous recordings of sleep metrics.

    We will assess time spent in NonREM stages 1 (N1), 2 (N2) and 3 (N3) sleep and REM sleep (RS), latency to sleep onset (SOL), and wake after sleep onset (WASO). We will also assess delta power during sleep stages and wake; and overall sleep maintenance (SM) and sleep efficiency (SE). Diminished time spent in SOL and WASO, increased time N2, N3 and REM sleep, increased delta during NonREM sleep are each signs of improved sleep. Increases in SM and SE indicated improved, more stable sleep patterns

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  3. mean change in Change in Mnemonic Discrimination over time

    Mnemonic discrimination task tests recognition memory for common objects, as reported in scores on a scale of the Lure Discrimination Index ranging from 0.00 to 1.00 where higher values show better performance.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  4. mean change in Task-based Cortical Functional Connectivity

    functional MRI data associated With Training-induced Changes in Mnemonic Discrimination will be analyzed in terms of beta-series correlations between co-active cortical regions of interest and compared between treatment arms and timepoints.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  5. Mean Change on Everyday Cognition Scale (ECog)

    The Everyday Cognition Scale (ECog) measures the ability to perform everyday tasks that demand memory, language, visuospatial abilities, planning, organization, and divided attention. The ECog consists of a global and domain scores for each of the previously described categories, and is scored as follows: 1= better or no change compared to 10 years earlier, 2= questionable/occasionally worse compared to 10 years earlier, 3= consistently a little worse compared to 10 years earlier, 4= consistently much worse compared to 10 years earlier. Thus, the lower the overall score is on this measure at both the global and domain score level, the better one is performing with respect to their cognition.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  6. Mean Change on SF-36 (overall health)

    SF-36 (overall health) The general health and well-being (SF-36) score assesses participant health. The SF-36 score ranges from 0 to 100. The higher the overall score is on this measure, the better one is performing with respect to their health and well-being.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  7. Mean Change on Perceived Stress Scale

    Perceived Stress Scale A survey that measures the degree to which situations in one's life are perceived as stressful. Scores range from 0 to 40 with higher scores representing more perceived stress. We will report change in means over time.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  8. Mean Change on Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Overall scores range from 0 to 21, with lower scores representing healthier sleep quality. We will report change in means over time.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  9. Mean Change on Epworth Sleepiness Scale

    The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  10. Mean Change on Profile of Mood States

    POMS is a 65 questions psychometric instrument that measures the mood states of tension, depression, anger, vigor, fatigue, and confusion.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  11. Mean Change on Berlin Questionnaire

    The Berlin Questionnaire consists of 3 categories of questions related to the risk of having sleep apnea. Patients can be classified into High Risk or Low Risk based on their responses to the individual items and their overall scores in the symptom categories.

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

  12. Mean Change on Insomnia Severity Index

    The Insomnia Severity Index (ISI) is a brief screening tool for insomnia. It consists of seven questions regarding the nature and symptoms of sleep problems that respondents rate using a Likert scale ranging from 0 to 4. A total score of 0-7 indicates "no clinically significant insomnia," 8-14 means "subthreshold insomnia," 15-21 is "clinical insomnia (moderate severity)," and 22-28 means "clinical insomnia (severe).

    Time frame: baseline, immediate follow-up, and at a 6 month follow-up in a subset of participants

07

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94158, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06633978
Lead sponsor
University of California, San Francisco
Collaborators
National Institute on Aging (NIA)
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Sep 10, 2024
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Aug 24, 2026

Study contacts

David A Ziegler, PhD
principal investigator · University of California, San Francisco
Christine Walsh, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion